Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Common Equity (2016 - 2026)

Ironwood Pharmaceuticals' Common Equity history spans 17 years, with the latest figure at -$261.8 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 13.11% to -$261.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$261.8 million, a 13.11% increase, with the full-year FY2025 number at -$261.8 million, up 13.11% from a year prior.
  • Common Equity hit -$261.8 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$264.2 million in the prior quarter.
  • Over the last five years, Common Equity for IRWD hit a ceiling of $706.9 million in Q1 2023 and a floor of -$346.8 million in Q2 2023.
  • Historically, Common Equity has averaged $85.0 million across 5 years, with a median of -$132.4 million in 2023.
  • Biggest five-year swings in Common Equity: surged 9722.85% in 2021 and later tumbled 9841.77% in 2024.
  • Tracing IRWD's Common Equity over 5 years: stood at $605.9 million in 2021, then increased by 7.67% to $652.4 million in 2022, then plummeted by 100.46% to -$3.0 million in 2023, then tumbled by 9841.77% to -$301.3 million in 2024, then grew by 13.11% to -$261.8 million in 2025.
  • Business Quant data shows Common Equity for IRWD at -$261.8 million in Q4 2025, -$264.2 million in Q3 2025, and -$308.2 million in Q2 2025.